BM-PEG3

CAS No. 86099-06-1

BM-PEG3( 1,11-Bis-maleimidotetraethyleneglycol )

Catalog No. M24856 CAS No. 86099-06-1

BM-PEG3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
50MG 59 In Stock
100MG 87 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BM-PEG3
  • Note
    Research use only, not for human use.
  • Brief Description
    BM-PEG3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • Description
    BM-PEG3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • In Vitro
    PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
  • In Vivo
    ——
  • Synonyms
    1,11-Bis-maleimidotetraethyleneglycol
  • Pathway
    PROTACs
  • Target
    PROTAC
  • Recptor
    PEGs
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    86099-06-1
  • Formula Weight
    352.34
  • Molecular Formula
    C16H20N2O7
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:10 mM
  • SMILES
    O=C(C=CC1=O)N1CCOCCOCCOCCN2C(C=CC2=O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.
molnova catalog
related products
  • Bromo-PEG2-CH2-Boc

    Bromo-PEG2-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

  • Bromo-PEG3-C2-acid

    Bromo-PEG3-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

  • MS4077

    MS4077 is a novel PROTAC (degrader) of ALK, potently decreases cellular levels of oncogenic active ALK fusion proteins in a concentration- and time-dependent manner in SU-DHL-1 lymphoma and NCI-H2228 lung cancer cells (DC50=3 nM).